Johnson & Johnson (NYSE:JNJ) has been assigned a $147.00 target price by research analysts at Cowen and Company in a note issued to investors on Friday. The brokerage currently has a “buy” rating on the stock. Cowen and Company’s target price would suggest a potential upside of 10.34% from the stock’s previous close.

A number of other research analysts have also recently commented on the company. Zacks Investment Research upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Wednesday. Piper Jaffray Companies restated a “hold” rating and set a $120.00 price objective on shares of Johnson & Johnson in a research note on Wednesday. UBS AG restated a “buy” rating and set a $148.00 price objective on shares of Johnson & Johnson in a research note on Saturday, September 30th. Citigroup Inc. began coverage on Johnson & Johnson in a research note on Monday, September 25th. They set a “neutral” rating and a $140.00 price objective on the stock. Finally, Goldman Sachs Group, Inc. (The) cut Johnson & Johnson from a “neutral” rating to a “sell” rating and boosted their price objective for the stock from $125.00 to $130.00 in a research note on Wednesday, September 20th. Five analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $134.79.

Johnson & Johnson (NYSE:JNJ) traded up 0.02% during midday trading on Friday, hitting $133.22. The company had a trading volume of 2,469,473 shares. The firm has a market cap of $357.56 billion, a price-to-earnings ratio of 22.54 and a beta of 0.78. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $137.08. The stock has a 50 day moving average of $132.23 and a 200 day moving average of $129.83.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. During the same quarter last year, the firm earned $1.74 earnings per share. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. On average, analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Johnson & Johnson (JNJ) Given a $147.00 Price Target by Cowen and Company Analysts” was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/06/johnson-johnson-jnj-given-a-147-00-price-target-by-cowen-and-company-analysts.html.

In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the sale, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. Insiders own 0.19% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Harding Loevner LP acquired a new stake in Johnson & Johnson in the second quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the period. Lenox Wealth Advisors Inc. lifted its position in Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares during the period. IHT Wealth Management LLC lifted its position in Johnson & Johnson by 46.4% in the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after purchasing an additional 3,467 shares during the period. Finally, Mountain Capital Investment Advisors Inc acquired a new stake in Johnson & Johnson in the second quarter worth approximately $124,000. Hedge funds and other institutional investors own 65.90% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.